Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome

17 Aug 2011

Abstract excerpt

PURPOSE: The DNA methylation inhibitor 5-aza-2'-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndromes (MDS), but resistance to DAC develops during treatment and mechanisms of resistance remain unknown. Therefore, we investigated mechanisms of primary and secondary resistance to DAC in MDS. PATIENTS AND METHODS: We performed Quantitative Real-Time PCR to examine expression of genes related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Blood disorders and treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21858090
DOI: 10.1371/journal.pone.0023372

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Resistance to Decitabine in the Myelodysplastic SyndromePMID 21858090Read ↗

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].Semantic proximity Read ↗

Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies TreatmentSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesSemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Demethylating agents in myeloid malignanciesSemantic proximity Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid LeukemiaSemantic proximity Read ↗

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.